Contribute Try STAT+ Today

In an unusual move, Pacira Biosciences (PCRX) has filed a libel lawsuit against a medical journal, its editor, and the authors of several recently published papers, arguing the articles were based on “faulty scientific research” and as a result, its only medicine was portrayed as ineffective.

The drug maker alleged the papers published this past February in Anesthesiology reflected a “bias” against its Exparel painkiller and “disparaged” the drug, which is used after surgeries. Consequently, customers have either canceled contracts, declined to purchase the drug, which is not an opioid, or are considering removing it from hospital formularies, according to the lawsuit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.